|
US2096883A
(en)
*
|
1933-07-19 |
1937-10-26 |
Electrolux Corp |
Vacuum cleaner
|
|
US5312820A
(en)
|
1992-07-17 |
1994-05-17 |
Merck & Co., Inc. |
Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
|
|
WO1994027597A1
(en)
*
|
1993-05-21 |
1994-12-08 |
Smithkline Beecham Corporation |
Imidazolyl-alkenoic acid angiotensin ii receptor antagonists
|
|
US5444067A
(en)
|
1993-08-30 |
1995-08-22 |
Merck & Co., Inc. |
Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
|
|
SE9800550D0
(sv)
|
1998-02-24 |
1998-02-24 |
A & Science Invest Ab |
A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
|
|
YU78601A
(sh)
*
|
1999-05-05 |
2005-07-19 |
Aventis Pharma Deutschland Gmbh. |
1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
|
|
CA2449150C
(en)
|
2001-05-31 |
2011-07-12 |
Vicore Pharma Ab |
Tricyclic compounds useful as angiotensin ii agonists
|
|
WO2004046141A1
(en)
|
2002-11-21 |
2004-06-03 |
Vicore Pharma Ab |
New tricyclic angiotensin ii agonists
|
|
US8835471B2
(en)
|
2010-06-11 |
2014-09-16 |
Vicore Pharma Ab |
Use of angiotensin II agonists
|
|
US9864250B2
(en)
*
|
2014-11-14 |
2018-01-09 |
Heliotrope Technologies, Inc. |
Post-temperable nanocrystal electrochromic devices
|
|
BR112017012337A2
(pt)
|
2014-12-12 |
2018-02-27 |
Vicore Pharma Ab |
Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
|
|
WO2016107879A2
(en)
|
2014-12-30 |
2016-07-07 |
Vicore Pharma Ab |
New use of angiotensin ii receptor agonists
|
|
CN107405406A
(zh)
*
|
2015-03-02 |
2017-11-28 |
维科尔药物公司 |
用于治疗肺纤维化的血管紧张素ii受体激动剂
|
|
WO2017221012A1
(en)
|
2016-06-21 |
2017-12-28 |
Vicore Pharma Ab |
Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
|
|
GB201710906D0
(en)
|
2017-07-06 |
2017-08-23 |
Vicore Pharma Ab |
Compounds and methods for treating peripheral neuropathy
|
|
GB201913603D0
(en)
*
|
2019-09-20 |
2019-11-06 |
Vicore Pharma Ab |
New compounds
|
|
US11123329B1
(en)
*
|
2020-03-23 |
2021-09-21 |
Vicore Pharma Ab |
Use of angiotensin II type 2 receptor agonist
|
|
GB202006079D0
(en)
*
|
2020-04-24 |
2020-06-10 |
Vicore Pharma Ab |
New composition
|
|
GB202006074D0
(en)
*
|
2020-04-24 |
2020-06-10 |
Vicore Pharma Ab |
New composition
|
|
GB202201723D0
(en)
*
|
2022-02-10 |
2022-03-30 |
Vicore Pharma Ab |
New use
|
|
WO2023152503A1
(en)
*
|
2022-02-10 |
2023-08-17 |
Vicore Pharma Ab |
Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
|